Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | MASP2 | O00187 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purine SCHEMBL6434254 | 0.88 | ALDH1A1 (0.40) | EGFRALDH1A1MEN1KMT2ANUDT1 | |
| SCHEMBL9572676 | 0.77 | EGFR (0.33) | EGFR | |
| SCHEMBL7948683 | 0.77 | EGFR (0.33) | EGFR | |
| SCHEMBL2011130 | 0.77 | EGFR (0.33) | EGFR | |
| SCHEMBL1586125 | 0.77 | EGFR (0.33) | EGFR | |
| SCHEMBL7702472 | 0.77 | RPS6KA5 (0.35) | EGFR | |
| SCHEMBL1963573 | 0.77 | ADORA2A (0.36) | EGFR | |
| SCHEMBL1021063 | 0.77 | EGFR (0.33) | EGFR | |
| SCHEMBL9652879 | 0.77 | EGFR (0.33) | EGFR | |
| SCHEMBL2141779 | 0.77 | EGFR (0.34) | EGFRALDH1A1SMN1; SMN2HSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | claimed |
| CN-103068834-A | Phosphoramidites for reverse RNA synthesis | CHEMGENES CORP | 2013-04-24 | — | — | CN | claimed |
| EP-2560982-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | Chemgenes Corporation (US) | 2013-02-27 | — | — | EP | claimed |
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | claimed |
| EP-2398815-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | Chemgenes Corporation (US) | 2011-12-28 | — | — | EP | claimed |
| WO-2011103468-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | CHEMGENES CORPORATION (US) | 2011-08-25 | — | — | WO | claimed |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | CHEMGENES CORPORATION (US) | 2011-06-09 | — | — | US | claimed |
| WO-2010096201-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION (US) | 2010-08-26 | — | — | WO | claimed |
| EP-1507873-A4 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | CYGENE INC (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1730158-A2 | METHODS AND COMPOSITIONS FOR IN VITRO AND IN VIVO USE OF PARALLEL STRANDED HAIRPINS AND TRIPLEX STRUCTURES AS NUCLEIC ACID LIGANDS | Cygene, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005025495-A2 | METHODS AND COMPOSITIONS FOR BLOCKING PROGRESSION OF A DISEASE STATE | CYGENE LABORATORIES, INC. (US) | 2005-03-24 | — | — | WO | claimed |
| EP-1507873-A1 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | Cygene, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| US-20050014164-A1 | Triplex-forming oligonucleotides containing modified purines and their applications | ERITJA RAMON (ES) | 2005-01-20 | — | — | US | claimed |
| US-20040137431-A1 | Target sequences for the detection of the west nile virus | ERITJA RAMON (ES) | 2004-07-15 | — | — | US | claimed |
| WO-2004042362-A2 | TARGET SEQUENCES FOR THE DETECTION OF THE WEST NILE VIRUS | CYGENE LABORATORIES, INC. (US) | 2004-05-21 | — | — | WO | claimed |
| WO-2004037981-A2 | TRIPLEX-FORMING OLIGONUCLEOTIDES CONTAINING MODIFIED PURINES AND THEIR APPLICATIONS | CYGENE LABORATORIES, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040029160-A1 | Parallel stranded duplexes of deoxyribonucleic acid and methods of use | CYGENE, INC. | 2004-02-12 | — | — | US | claimed |
| WO-2003100099-A1 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | CYGENE, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-5449664-A | Nucleosides | SYNTEX (U.S.A.) INC. (US) | 1995-09-12 | — | — | US | claimed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | TYMP, MTAP, GART | EGFR 2484/4885ALDH1A1 3050/4885MEN1 3245/4885 |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | NSUN3, RNGTT, NOP2 | EGFR 4170/4885ALDH1A1 4050/4885MEN1 3293/4885 |
| US-20040029160-A1 | Parallel stranded duplexes of deoxyribonucleic acid and methods of use | DDX18, DDX1, ADAR | EGFR 4200/4885ALDH1A1 2886/4885MEN1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.